Definium Therapeutics Inc (DFTX)

Aug 20, 2026

DRIEHAUS CAPITAL MANAGEMENT LLC Expands Definium Therapeutics In - GuruFocus

Aug 20, 2026

Aug 20, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 20, 2026

Aug 20, 2026

Traders Purchase High Volume of Definium Therapeutics Call Options (NASDAQ:DFTX) - MarketBeat

Aug 20, 2026

Aug 20, 2026

Definium Therapeutics (DFTX) Could Be 22% Undervalued On Positive Phase 3 Voyage Results - Sahm

Aug 20, 2026

Aug 19, 2026

Total non-current assets of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView

Aug 19, 2026

Aug 19, 2026

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm

Aug 19, 2026

Aug 19, 2026

DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits

Aug 19, 2026

Aug 18, 2026

Definium Therapeutics Posts Strong Phase 3 GAD Data for DT120 - TipRanks

Aug 18, 2026

Aug 18, 2026

Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Bank of America - MarketBeat

Aug 18, 2026

Aug 18, 2026

Definium Therapeutics (DFTX) Is Down 5.6% After Positive Phase 3 GAD Data For DT120 ODT - Sahm

Aug 18, 2026

Aug 18, 2026

DFTX Initiates Coverage On B of A Securities -- Rating Set to Bu - GuruFocus

Aug 18, 2026

Aug 18, 2026

Definium Therapeutics Announces New Employee Inducement GrantsAugust 17, 2026 - BioSpace

Aug 18, 2026

Aug 17, 2026

BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential - Investing.com Nigeria

Aug 17, 2026

Aug 17, 2026

Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat

Aug 17, 2026

Aug 17, 2026

Definium Therapeutics (DFTX) Reports Positive Phase 3 GAD Trial Results Amid High Valuation - GuruFocus

Aug 17, 2026

Aug 17, 2026

DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits

Aug 17, 2026

Aug 14, 2026

DFTX Maintained by Maxim Group -- Price Target Raised to $55 - GuruFocus

Aug 14, 2026

Aug 14, 2026

Definium Therapeutics Price Target Raised to $55.00/Share From $50.00 by Maxim Group - Moomoo

Aug 14, 2026

Aug 14, 2026

Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake - Stock Titan

Aug 14, 2026

Aug 14, 2026

Definium Therapeutics' Voyage Trial Success Reshapes Valuation Debate for Anxiety Drug - finance.biggo.com

Aug 14, 2026

Aug 14, 2026

DFTX News Today | Why did Definium Therapeutics stock go down today? - MarketBeat

Aug 14, 2026

Aug 14, 2026

Driehaus Capital trims percentage stake in Definium Therapeutics (DFTX) to 5.36% - Stock Titan

Aug 14, 2026

Aug 14, 2026

Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus - Yahoo Finance

Aug 14, 2026

Aug 13, 2026

Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says - Moomoo

Aug 13, 2026

Aug 13, 2026

Is Successful Voyage Phase 3 Data Transforming the Investment Case For Definium Therapeutics (DFTX)? - Yahoo Finance

Aug 13, 2026

Aug 13, 2026

DFTX Maintained by Jones Trading -- Price Target Raised to $90.0 - GuruFocus

Aug 13, 2026

Aug 13, 2026

Definium says LSD-based pill reduces anxiety in late-stage study - Reuters

Aug 13, 2026

Aug 13, 2026

Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $90.00 at JonesTrading - MarketBeat

Aug 13, 2026

Aug 13, 2026

DFTX Maintained by Canaccord Genuity -- Price Target Raised to $64 - GuruFocus

Aug 13, 2026

Aug 13, 2026

Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT - Yahoo Finance

Aug 13, 2026

Aug 13, 2026

DFTX Maintained by RBC Capital -- Price Target Raised to $66.00 - GuruFocus

Aug 13, 2026

Aug 13, 2026

Royal Bank Of Canada Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock - MarketBeat

Aug 13, 2026

Aug 13, 2026

DFTX Maintained by Wells Fargo -- Price Target Raised to $72 - GuruFocus

Aug 13, 2026

Aug 13, 2026

Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $72.00 at Wells Fargo & Company - MarketBeat

Aug 13, 2026

Aug 13, 2026

JonesTrading Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $90 - Moomoo

Aug 13, 2026

Aug 13, 2026

Definium Phase III success with DT120 in anxiety - The Pharma Letter

Aug 13, 2026

Aug 13, 2026

Robert W. Baird Increases Definium Therapeutics (NASDAQ:DFTX) Price Target to $75.00 - MarketBeat

Aug 13, 2026

Aug 13, 2026

Canaccord raises Definium Therapeutics price target on trial data By Investing.com - Investing.com Nigeria

Aug 13, 2026

Aug 13, 2026

Canaccord raises Definium Therapeutics price target on trial data - Investing.com

Aug 13, 2026

Aug 13, 2026

DFTX Maintained by Baird -- Price Target Raised to $75.00 - GuruFocus

Aug 13, 2026

Aug 13, 2026

RBC Adjusts PT on Definium Therapeutics to $66 From $57, Keeps Outperform Speculative Risk Rating - marketscreener.com

Aug 13, 2026

Aug 13, 2026

Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study - MarketBeat

Aug 13, 2026

Aug 12, 2026

Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst - Seeking Alpha

Aug 12, 2026

Aug 12, 2026

DFTX Maintained by Needham -- Price Target Raised to $66.00 - GuruFocus

Aug 12, 2026

Aug 12, 2026

Needham & Company LLC Raises Definium Therapeutics (NASDAQ:DFTX) Price Target to $66.00 - MarketBeat

Aug 12, 2026

Aug 12, 2026

DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’ - TradingView

Aug 12, 2026